度洛西汀和氟西汀治疗老年期抑郁症的对照研究  

Study on the effects of duloxetine and fluxetine on late-onset patients with depression

作　　者：刘晓伟[1] 杨雀屏[1] 朱培俊[1] 王进良[1] 

机构地区：[1]南京医科大学附属无锡市精神卫生中心精神科,江苏省无锡市214151

出　　处：《实用老年医学》2010年第2期162-164,共3页Practical Geriatrics

摘　　要：目的评估度洛西汀治疗老年期抑郁症的临床疗效和安全性。方法将72例老年期抑郁症患者随机分为度洛西汀组和氟西汀组,各36例,疗程为8周。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定疗效,采用不良反应量表(TESS)评定安全性。结果治疗8周末,2组间总体疗效差异无显著性。HAMD和HAMA总分治疗前后差异有显著性(P<0.05),2组间比较无统计学差异,但焦虑/躯体化、睡眠障碍等因子分比较,2组间差异有显著性。2组间不良反应比较差异无显著性。结论度洛西汀治疗老年期抑郁症疗效好,安全性高,临床上特别适用于伴有躯体化症状的抑郁症老年患者。ObjectiveTo evaluate the efficacy and safety of duloxetine in the treatment for lateonset patients with depression. MethodsSeventytwo lateonset patients with depression were randomly divided into study group （receiving duloxetine） and control group （receiving fluxetine）. Efficacy and side effects were assessed with HAMD, HAMA and TESS respectively before and after treatment. ResultsAfter eight weeks, the efficacy showed no differences between two groups. No significant difference was found in all scores of HAMD and HAMA between the two groups. But the scores of anxiety / somatization and sleep disorder in study group were significantly different from control group. No difference was found in the adverse event between the two groups. ConclusionsDuloxetine shows better efficacy and high safety in the treatment of lateonset depression, which could be recommended to all lateonset patients with somatization symptoms.

关 键 词：度洛西汀 氟西汀 老年期 抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]